Journal
CURRENT ALZHEIMER RESEARCH
Volume 6, Issue 5, Pages 446-450Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/156720509789207930
Keywords
Tau; immunotherapy; vaccine; immunization; phosphorylation
Categories
Funding
- NIA NIH HHS [R01 AG020197-03, R01 AG020197-05, R01 AG020197-07, R01 AG032611-01, R01 AG020197-01, AG032611, R01 AG020197-06A2, R01 AG020197-04, AG02197, R01 AG020197-02, R01 AG020197, R01 AG032611] Funding Source: Medline
- NIDDK NIH HHS [R21 DK075494-01A1, R21 DK075494, DK075494, R21 DK075494-02] Funding Source: Medline
Ask authors/readers for more resources
Immunotherapies targeting the amyloid-beta (A beta) peptide in Alzheimer's disease (AD) have consistently been effective in mouse studies and shown promise in clinical trials, although some setbacks have occurred. First, encephalitis was observed in a small subset of patients. More recent autopsy data from a few subjects suggests that clearance of A beta plaques may not halt cognitive deterioration once impairments are evident, emphasizing the need for other more effective approaches at that stage of the disease. Another important target in AD is the neurofibrillary tangles and its precursors, composed primarily of hyperphosphorylated tau proteins, which correlate well with the degree of dementia. As A beta and tau pathologies are likely synergistic, targeting both together may be more effective, and perhaps essential as early diagnosis prior to cognitive decline is currently unavailable. Also, A beta immunotherapy results in a very limited indirect clearance of tau aggregates, showing the importance of developing a separate therapy that directly targets pathological tau. Our findings in two tangle mouse models indicate that active immunization targeting an AD phospho-tau epitope reduces aggregated tau in the brain and prevents/slows progression of the tangle-related behavioral phenotype, including cognitive impairment. These antibodies enter the brain and bind to pathological tau within neurons although the therapeutic effect may at least in part be due to clearance of extracellular tau that may have biological effects. We are currently clarifying the mechanism of these promising findings, determining its epitope specificity as well as assessing the feasibility of this approach for clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available